

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2696)

APPOINTMENT OF PRESIDENT

The board of directors (the “**Board**”) of Shanghai Henlius Biotech, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that based on the nomination of Mr. Jun Zhu (“**Mr. Zhu**”), the Chief Executive Officer (“**CEO**”) of the Company, Ms. Wei Huang (“**Ms. Huang**”) has been appointed as the President (“**President**”) of the Company with effect from 1 October 2023. Ms. Huang is mainly responsible for the production quality operation and engineering project construction management of the Company, and business decisions of the Company’s subsidiary, Aton (Shanghai) Biotech Co., Ltd., and will report to Mr. Zhu, the CEO. Mr. Zhu ceased to be the President with effect from the same date but will continue to act as the executive director, CEO and Chief Financial Officer of the Company.

Ms. Huang, aged 55, joined the Group in December 2019 and served as the senior vice president of Shanghai Henlius Biopharmaceutical Co., Ltd., a subsidiary of the Company, and served as the senior vice president and chief operating officer of the Company since October 2020. Prior to joining the Group, Ms. Huang has around 25 years of senior management and leadership experience in the pharmaceutical and biotechnology industries, including process development, technology transfer, manufacturing, engineering project construction management, etc.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 3 October 2023

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and executive director, Mr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive directors.